Drugs News and Research

RSS

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was US$300 million.

2 Sep 2015

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

2 Sep 2015

World Hepatitis Summit highlights need to develop national programmes that can eliminate viral hepatitis

Participants at the first-ever World Hepatitis Summit will urge countries to develop national programmes that can ultimately eliminate viral hepatitis as a problem of public health concern.

2 Sep 2015

Huntington’s disease prevention breakthrough? An interview with Professor Lesley Jones

Huntington’s disease is an inherited disease which, whilst quite rare, is one of the more common inherited neurodegenerative diseases. About 1 in 6,000 people in the UK are at risk and what’s horrible about this disease is that if one of your parents has it, then you have a fifty-fifty chance of inheriting it.

2 Sep 2015

USF, FARA to jointly host scientific symposium on Friedreich's ataxia

The University of South Florida will again bring together leading researchers and patients searching for a treatment for Friedreich's ataxia and related disorders at the seventh annual scientific symposium "Understanding Energy for A Cure." The symposium will be held 5 to 8:30 p.m., Thursday, Sept. 17, at the USF Marshall Student Center Ballroom, USF Cedar Circle, Tampa, FL 33620.

2 Sep 2015

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal.

2 Sep 2015

Volatile anesthetics may combat viral and bacterial infections in the lung

In use for more than a century, inhaled anesthetics like nitrous oxide and halothane have made modern surgery possible. Now, in experiments in mice, researchers at Johns Hopkins and elsewhere have added to evidence that certain so-called "volatile" anesthetics -- commonly used during surgeries -- may also possess powerful effects on the immune system that can combat viral and bacterial infections in the lung, including influenza and pneumonia.

2 Sep 2015

Common antidepressant can help stroke patients improve movement and coordination

Working with mice, researchers at Johns Hopkins have added to evidence that a commonly prescribed antidepressant called fluoxetine helps stroke victims improve movement and coordination, and possibly why.

2 Sep 2015

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.

2 Sep 2015

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Researchers at the University of Maryland and the University of Virginia have performed the first focused ultrasound treatments in the United States for dyskinesia associated with Parkinson's disease.

2 Sep 2015

Diagnosing traumatic brain injury through a blood test: an interview with Dr Korley

The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not “mild”. Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don’t.

1 Sep 2015

North Shore-LIJ researcher compares safety benefits two blood-thinning medications

A large, ambitious contrast of blood-thinning medications used during cardiac stent placement suggests that a very expensive drug offers no clear safety benefits over a much more affordable option, according to a prominent North Shore-LIJ researcher and cardiologist.

1 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

SLU scientist receives grant to solve blood-clotting mysteries

Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs.

1 Sep 2015

IV drug abusers who undergo infective endocarditis surgery face higher risk of reoperation or death

Injection drug users who undergo surgery for infective endocarditis (IE) have a significantly higher risk of reoperation or death between 3 and 6 months after surgery compared to patients who develop endocarditis who are not IV drug abusers, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.

1 Sep 2015

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Preoperative statins are associated with a 17% reduction in cardiac complications and a 43% reduction in mortality after noncardiac surgery, according to results from the VISION Study presented for the first time today at ESC Congress by Dr Otavio Berwanger, director of the Research Institute HCor, Hospital do Coração (Heart Hospital) in São Paulo, Brazil.

1 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Experts to discuss research on lupus at world congress organized by MedUni Vienna

Lupus is an autoimmune disease with so many different symptoms that it is often difficult to diagnose and to treat. Despite huge medical advances over the last few years, lupus is incurable. Modern, individually tailored therapeutic approaches are aimed at helping sufferers. The world congress organized by MedUni Vienna brings experts from more than 80 countries together in Vienna from 2 to 6 September to discuss the latest research results and therapies.

1 Sep 2015

One in every 17 college students smokes marijuana on daily or near-daily basis

Daily marijuana use among the nation's college students is on the rise, surpassing daily cigarette smoking for the first time in 2014.

1 Sep 2015

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.

1 Sep 2015

Drugs News and Research

Ascletis completes US$35 million (RMB 220 million) financing

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

World Hepatitis Summit highlights need to develop national programmes that can eliminate viral hepatitis

Huntington’s disease prevention breakthrough? An interview with Professor Lesley Jones

USF, FARA to jointly host scientific symposium on Friedreich's ataxia

Treatment with life-saving medications increases in IHD but levels still suboptimal

Volatile anesthetics may combat viral and bacterial infections in the lung

Common antidepressant can help stroke patients improve movement and coordination

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Diagnosing traumatic brain injury through a blood test: an interview with Dr Korley

North Shore-LIJ researcher compares safety benefits two blood-thinning medications

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

SLU scientist receives grant to solve blood-clotting mysteries

IV drug abusers who undergo infective endocarditis surgery face higher risk of reoperation or death

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Experts to discuss research on lupus at world congress organized by MedUni Vienna

One in every 17 college students smokes marijuana on daily or near-daily basis

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News